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In current work, we present 3,6-di(pyridin-2-yl)-1,2,4,5-s-tetrazine (pytz) capped gold nanoparticles (TzAuNPs) as an 
potent antibacterial agent against Gram-positive bacteria. The antibacterial properties of TzAuNPs have been studied using 
Gram-positive Bacillus subtilis (ATCC 11774) by the plate count method and TzAuNPs is found to be highly effective 
against the strain. Furthermore, TzAuNPs also show significantly better antimicrobial activity against the bacterial strain 
when compared to pytz. The effect of TzAuNPs on the bacterial cell wall is also investigated by TEM analysis. This new 
antimicrobial material could be promising in future for the treatment infectious diseases caused by Gram-positive bacteria. 
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As a result of increasing microbial resistance to 
multiple antimicrobial agents and development of 
resistant strains, there is an increasing demand for 
novel antimicrobial materials with superior 
performance for disinfection applications1−8. 
Consequently, new agents and methods for bactericidal 
treatment of infections caused by bacteria are urgently 
needed. In this regard, nanomaterials are particularly 
effective and have shown great potential as a new drug 
to kill or inhibit numerous microorganisms.9−13 The 
antibacterial activity of nanoparticles is dependent on 
their direct interaction with the bacterial cell wall and 
they can, therefore, act as antibiotics without entry into 
the cell.14,15 Other possible modes of antibacterial 
action for nanoparticles include the generation of 
reactive oxygen species (ROS), penetration through the 
cell membrane and interactions with cellular DNA and 
proteins. As a result of these multiple modes of action, 
the use of nanoparticles as antibacterial agents would 
provide a greater barrier to bacteria developing 
resistance mechanisms that is the case for conventional 
therapeutics.7 Several metal nanoparticles (NPs) (e.g., 
silver, copper, gold) have been synthesized and tested 
for antimicrobial activity against several pathogenic 
bacterial strains. Gold nanoparticles (AuNPs) have 
recently attracted a lot of attention compared to other 
metal NPs due to low toxicity, chemical stability and 
easy surface functionalization. AuNPs have been 
extensively used in drug delivery applications, 
intracellular gene regulation, bioimaging 
(as contrast agents), anti-inflammatory therapy and 
anticancer therapy (photodiagnostic and photothermal 
therapy).16−22 Furthermore, the antimicrobial activity 
of gold nanoparticles has been recently 
demonstrated.15,21−25 
In this work, a simple, eco-friendly, and cost-
effective synthesis method of AuNPs using 3,6-
di(pyridin-2-yl)-1,4-dihydro-1,2,4,5-tetrazine(H2pytz) 
as reducing agents has been reported. This 3, 6-di-
(pyridin-2-yl)-1,2,4,5-tetrazine (pytz) capped gold 
(TzAuNPs) nanoparticles have been synthesized to 
investigate their potential against bacterial growth. 
The antibacterial activity of the TzAuNPs against 
Gram-positive Bacillus subtilis and Gram-negative 
E. coli K12 has been studied.
Materials and Methods 
The syntheses of 3, 6-di(pyridin-2-yl)-1,2,4, 
5-tetrazine (pytz) capped Au(0) nanoparticles were
carried out according to the method reported earlier.26
Standard strain of Bacillus subtilis (ATCC 11774)
was utilized to determine antibacterial activities.




3,6-Di(pyridin-2-yl)-1,2,4,5-s-tetrazine (pytz) capped-gold 
nanoparticles (TzAuNPs) 
The synthesis of 3,6-di(pyridin-2-yl)-1,2,4,5-s-
tetrazine (pytz) capped-gold nanoparticles (TzAuNPs) 
was achieved by the reduction of HAuCl4·3H2O  
with 3,6-di(pyridin-2-yl)-1,4-dihydro-1,2,4,5-tetrazine 
(H2pytz). A 100 mL round bottom flask containing 
solution of 3,6-di(pyridin-2-yl)-1,4-dihydro-1,2,4,5-
tetrazine (0.12 g, 0.5 mmol) in ethanol (50 mL) was 
placed in an ultrasonicator bath and hydrogen 
tetrachloroaurate(III) (0.3 g, 0.75 mmol) in 10 mL 
water was added to it drop wise. After few minutes, a 
reddish black precipitate started to appear slowly 
indicating the formation of gold nanoparticles. The 
resulting particles were isolated by centrifugation  
(10 min, 12000 rpm) and washed subsequently with 
water, ethanol, and dichloromethane. The product was 
then dried in vacuum oven and kept in vacuum 
desiccator for further characterization. 
 
Characterization of nanoparticles 
Powder X-ray diffraction (XRD) patterns were 
obtained on a Philips PW 1140 parallel beam  
X-ray diffractometer with Bragg-Bretano focusing 
geometry and monochromatic CuK radiation  
( = 1.540598 Å). Transmission electron microscopy 
(TEM) images were collected by using JEOL JEM-
2100 microscope working at 200 kV. TEM samples 
were prepared by sonicating an aliquot of the sample 
in ethanol for 15 min and 1 L of this suspension was 
drop-casted onto carbon-coated, 300 mesh copper 
grids. Grids were allowed to dry in descicator  
prior to imaging. 
 
Antimicrobial test for TzAuNPs 
The antibacterial activities of TzAuNPs were 
measured by serial dilution method. The 50 mg of 
nanoparticles were as suspended in 6 mL of Muller-
Hinton Broth and inoculated with 1 mL of 18 h stock 
culture of Escherichia coli K12 and Bacillus subtilis. 
Aliquots of each sample were diluted and  
200 L plated on sterile Petridishes, covered with 
Muller-Hinton Agar. The plates were incubated for  
20 h at 37 °C. After the incubation period, the colony 
forming units (CFU) of each plate were determined. 
Antimicrobial activity of pytz was also tested by the 
same method to compare its activity with TzAuNPs. 
 
Minimum inhibitory concentration (MIC) of TzAuNPs 
Bacillus subtilis was respectively cultured in 
Muller-Hinton broth at 37 °C on a shaker incubator at 
200 rpm for 6 h. Then the concentration of 
microorganism of 1×108 CFU mL−1 dilution was fixed 
at 0.1 optical density at 600 nm with adding medium 
and then again diluted to 1×106 CFU mL−1 with medium. 
We mixed bacterial suspension (1×106 CFU mL−1,  
100 L mL−1) with the solutions of pytz capped-gold 
nanoparticles with different concentrations in medium 
and the final volume of the solutions were adjusted to 
10 ml with medium. The solutions were shaken at 37 °C 
on a shaker incubator at 200 rpm for 24 h. The 
bacterial viability was determined by measuring 
optical density at 600 nm (OD600 nm). Simultaneously, 
aliquots of each solution were diluted and plated on 
Muller-Hinton Agar. The plates were incubated at 37 °C 
for 20 h and colonies were counted and compared to 
those on control plates to calculate changes in the cell 
growth inhibition. The percentage of cell  
growth reduction (R, %) was calculated using the 
following equation: 




Where C0 is the number of CFU from the control 
sample and C is the number of CFU from treated 
samples. Each concentration was prepared and 
measured in triplicate.  
 
Antibacterial growth kinetics of Bacillus subtilis 
Approximately 1×107 CFU mL−1 bacterial 
suspension was inoculated with different 
concentrations of TzAuNPs (3.75−17 μgmL−1) in 
Muller-Hinton Broth. The mixtures were shaken at  
37 °C on a shaker incubator at 200 rpm for 0–36 h. 
The initial time of addition of the bacteria was taken 
as zero. The growth curves resulted from bacteria 
only, and pytz capped-gold nanoparticles incubated 
with bacteria were plotted against time. Aliquots were 
withdrawn from each of the mixtures at definite time 
intervals and diluted further. 200 μL of the final 
solutions was plated on Muller-Hinton agar plates 
immediately. The plates were incubated at  
37 °C for 24 h, and bacterial colonies were counted. A 
plot of colony forming unit (CFU) in logarithmic 
scale versus time (log10 CFU mL
−1 vs time) was then 
plotted to determine the bactericidal kinetics.  
 
Characterization of treated bacteria by TEM 
The sizes and morphologies of TzAuNPs treated 
and untreated bacteria were examined by TEM. Prior 
to microscopy analysis, bacteria samples were 
prepared using procedures described previously in 




literature.27 Bacillus subtilis was inoculated for 10 h 
in Muller-Hinton broth at 37 °C and at 200 rpm until 
an OD600 of 0.5 was attained. The bacteria cells  
(30 mL) were then harvested, centrifuged, and  
re-dispersed in pH 7.4 PBS buffer. Pytz capped-gold 
nanoparticles were added to bacteria and the mixture 
was incubated at 37 °C for 6 h while shaking at  
200 rpm. The mixture was then centrifuged at 2000  
G-force for 8 min, and the supernatant containing was 
discarded. 1 L of bacteria cell suspension was placed 
onto a Cu grid followed by drying overnight in  
a desiccator. 
 
Results and Discussion 
Synthesis and Characterization of TzAuNPs 
The synthesis of 3,6-di(pyridin-2-yl)-1,2,4,5-s-
tetrazine (pytz)capped-gold nanoparticles (TzAuNPs) 
was carried following a method reported earlier for 
silver nanoparticles.26 In this synthesis, 3, 6-
di(pyridin-2-yl)-1,4-dihydro-1,2,4,5-tetrazine(H2pytz) 
acts as reducing agent for HAuCl4·3H2O and H2pytz 
oxidizes to (pytz)which eventually capped AuNPs to 
produce TzAuNPs. The present process does not need 
any external capping agent for stabilization of AuNPs. 
The capping of AuNPswith pytz not only controls the 
aggregation of AuNPs but also helps AuNPs to 
remain soluble in water. 
The crystallinity and purity of TzAuNPs were 
examined by the XRD technique. Fig. 1 depicts the 
XRD pattern of TzAuNPs. The XRD pattern of 
TzAuNPs shows that the AuNPs are highly crystalline 
and XRD peaks correspond to (111), (200), (220), 
(311) and (222) planes of Au(0) with fcc structure 
(JCPDS No. 04-0784).  
The morphology and size distribution of the 
prepared AuNps were elucidated from the 
transmission electron micrographs. Fig. 2 exhibits 
morphological images of the prepared TzAuNPs. 
Typical TEM images in Fig. 2, illustrates that the 
TzAuNPs are spherical in shape with average 
diameter of about 12 nm, albeit, the particles have a 
broader size distribution ranging from 5 to 20 nm. 
 
Antibacterial activity of TzAuNPs 
The antibacterial activities of TzAuNPs are 
evaluated for Gram-negative E. coli K12 and  
Gram-positive B. subtilis. TzAuNPs (50 mg) was 
dispersed in 6 mL of Mueller-Hinton broth and 
inoculated with 1 ml freshly cultured bacteria. After 
an incubation time of 18 h, sample was diluted and 
plated on Mueller-Hinton agar plates. The plates were 
incubated for 20 h. Colonies were counted and 
recorded for dilutions containing between 30 and  
300 colonies. In presence of TzAuNPs, the Mueller-
Hinton agar plates with B. subtilis exhibited no 
growth of bacterial colonies for 109–107 CFU mL1 
concentrations of bacteria, indicating excellent 
antibacterial activity of TzAuNPs against Gram-
positive bacteria (Fig. 3). On the other hand, 
TzAuNPs exhibited very poor activity against Gram-
negative E. coli. Antibacterial activities of TzAuNPs 
against B. subtilis were then compared with pytz and 
a control solution was prepared with the bacteria 
 
 
Fig. 1 — X-Ray diffraction pattern of 3,6-di(pyridin-2-yl)-1,2,4,5-
s-tetrazinecapped gold nanoparticles (TzAuNPs) 
 
 
Fig. 2 — TEM images of 3,6-di(pyridin-2-yl)-1,2,4,5-s-
tetrazinecapped-gold nanoparticles (TzAuNPs) 
 
 
Fig. 3 — Antibacterial activities of TzAuNPs with 109, 108 and 
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formation of blebs and collapse of bacterial cells  
(Figs 6b and 6c) as compared to control where very 
smooth morphology was observed (Fig. 6a). 
 
Conclusions 
3,6-Di(pyridin-2-yl)-1,2,4,5-tetrazine (pytz) capped 
gold (TzAuNPs) was synthesized and characterized by 
powder XRD and TEM techniques. A systematic 
evaluation of the antibacterial activities of the pytz-
capped Au(0) nanoparticle were carried out. TzAuNPs 
showed excellent bactericidal properties against Gram-
positive B. subtilis bacteria. The MIC value for 
TzAuNPs against B. subtilis was obtained as 3.75 μg 
mL1. The material reported here can effectively be used 
for different applications in biomaterials. 
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